Theolytics

Most cancer drugs struggle to penetrate solid tumours, and often miss the cells that support their growth.

Theolytics is developing oncolytic viruses that selectively infect and destroy cancer cells, while activating the immune system to help eliminate tumours. Powered by their proprietary bioselection platform, the company’s lead clinical stage programme targets ovarian cancer – with broader potential across solid tumours where conventional treatments fall short.